These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 19350459)
21. 19th Society for Neuro-Oncology Annual Meeting. Collingridge D Lancet Oncol; 2015 Jan; 16(1):18. PubMed ID: 25638541 [No Abstract] [Full Text] [Related]
22. The potential of DNA modifications as biomarkers and therapeutic targets in oncology. Jankowska AM; Millward CL; Caldwell CW Expert Rev Mol Diagn; 2015; 15(10):1325-37. PubMed ID: 26394702 [TBL] [Abstract][Full Text] [Related]
23. Next-Generation Sequencing in Oncology in the Era of Precision Medicine. Blumenthal GM; Mansfield E; Pazdur R JAMA Oncol; 2016 Jan; 2(1):13-4. PubMed ID: 26540172 [No Abstract] [Full Text] [Related]
24. Nanosensors for early cancer detection and for therapeutic drug monitoring. Salvati E; Stellacci F; Krol S Nanomedicine (Lond); 2015; 10(23):3495-512. PubMed ID: 26606949 [TBL] [Abstract][Full Text] [Related]
25. 'Flat-fixed dosing' of chemotherapy: a concept whose time has come? Markman M Curr Oncol Rep; 2005 Jan; 7(1):1-2. PubMed ID: 15610676 [No Abstract] [Full Text] [Related]
26. American Association for Cancer Research 98th Annual Meeting. Filson S; Kneller S; Sovran L IDrugs; 2007 Jun; 10(6):353-5. PubMed ID: 17641992 [No Abstract] [Full Text] [Related]
27. Contributions of 3D Cell Cultures for Cancer Research. Ravi M; Ramesh A; Pattabhi A J Cell Physiol; 2017 Oct; 232(10):2679-2697. PubMed ID: 27791270 [TBL] [Abstract][Full Text] [Related]
28. 43th ISOBM Annual Congress of International Society of Oncology and BioMarkers, September 1-6, 2016 Chicago, USA. Tumour Biol; 2016 Sep; 37 Suppl 1():1-45. PubMed ID: 27542676 [No Abstract] [Full Text] [Related]
29. "Therapeutic intent" in phase 1 oncology trials: a justifiable objective. Markman M Arch Intern Med; 2006 Jul; 166(14):1446-8. PubMed ID: 16864753 [No Abstract] [Full Text] [Related]
32. Introduction to special issue on biomarker-based clinical trial designs in oncology. Sargent DJ; Mandrekar S; Grothey A Chin Clin Oncol; 2015 Sep; 4(3):28. PubMed ID: 26408295 [No Abstract] [Full Text] [Related]
33. Cancer care expands to include genetic testing. Johns Hopkins Med Lett Health After 50; 2009 Jan; 20(11):4-5. PubMed ID: 19408409 [No Abstract] [Full Text] [Related]
34. Checkpoint inhibitors: a cutting edge in oncology. Jago C Drugs Today (Barc); 2017 Jul; 53(7):399-404. PubMed ID: 28837184 [TBL] [Abstract][Full Text] [Related]
36. 1st NCI annual meeting on Clinical Proteomic Technologies for Cancer. Tao F Expert Rev Proteomics; 2008 Feb; 5(1):17-20. PubMed ID: 18282119 [TBL] [Abstract][Full Text] [Related]
37. Pharmacologic biomarkers in the development of stratified cancer medicine. Figg WD; Newell DR Clin Cancer Res; 2014 May; 20(10):2525-9. PubMed ID: 24831275 [TBL] [Abstract][Full Text] [Related]
38. Integrating predictive biomarkers and classifiers into oncology clinical development programmes. Beckman RA; Clark J; Chen C Nat Rev Drug Discov; 2011 Sep; 10(10):735-48. PubMed ID: 21959287 [TBL] [Abstract][Full Text] [Related]
39. From traditional molecular biology to network oncology. Ziogas DE; Katsios C; Roukos DH Future Oncol; 2011 Feb; 7(2):155-9. PubMed ID: 21345133 [No Abstract] [Full Text] [Related]
40. American Association of Cancer Research--95th annual meeting. Highlights. 27-31 March, 2004, Orlando, FL, USA. Kibble A; Davies J IDrugs; 2004 May; 7(5):416-9. PubMed ID: 15154096 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]